Numerous studies on DTCs in EGFR-mutated lung cancers that followed the discovery of Sharma et al. [21] used short-term treatment with an EGFR TKI at clinically achievable concentrations to establish DTCs against EGFR TKIs (Figure 2A). This evidence concerns the gene EGFR and lung carcinoma.